South Carolina

  • Sam Patrick posted an article
    Greenville, SC gains more accolades as a key cog in the state's emerging knowledge economy see more

    Greenville and South Carolina are in the national spotlight again as among America's emerging knowledge economy destinations.  SCBIO supporters Zylo Therapeutics, KIYATEC, VentureSouth and Chartspan are among the features companies in Bloomberg Businessweek's fabulous article.  Read on for the full story.

     

  • Sam Patrick posted an article
    The Greenwood Genetic Center has named Richard Steet, PhD as Director of Research see more

    GREENWOOD, South Carolina – The Greenwood Genetic Center has named Richard Steet, PhD as Director of Research and Head of the JC Self Research Institute. He joins the GGC faculty from the University of Georgia where he was Professor of Biochemistry and Molecular Biology in the University’s Complex Carbohydrate Research Center.

    Steet’s research program, which is funded by the NIH and private foundations, is focused on defining disease mechanisms for two different classes of inherited diseases - lysosomal storage disorders and congenital disorders of glycosylation. Dr. Steet is also a dedicated advocate of rare disease research and serves on the scientific advisory boards for the National MPS Society and ISMRD, two organizations that provide family support and advance research.

    “I am thrilled to become part of the world-renowned Greenwood Genetic Center, and I look forward to collaborating with their clinical and diagnostic divisions to enhance our understanding of the genetic basis for birth defects and disabilities,” said Steet.

    Steet’s additional goals for the Center’s Research Division include integrating the Center’s strengths in basic science research with clinical and translational studies. He also plans to enhance partnerships with pharmaceutical companies that can drive therapeutic development for genetic disorders.

    Steet and Heather Flanagan-Steet, PhD, who also joins GGC’s faculty as Director of Functional Studies and Director of the Center’s new Aquaculture Facility, study both cell and animal-based models of human disease. Their work uses a combination of chemical, molecular, and developmental approaches to unravel the complexity of these disorders and explore new ways to treat them. Their efforts will dovetail in many ways with the mission of the Clemson Center for Human Genetics, located adjacent to the JC Self Research Institute. 

    The Steets have been working with GGC over the past several months to set up a new aquaculture facility at the Center that, once fully operational, will house over 10,000 zebrafish. The facility, along with a new confocal microscope, which will arrive at GGC this fall, will allow in depth characterization of zebrafish models for several human genetic diseases. Their zebrafish and cell models will be further leveraged to study challenging cases seen in the clinic and diagnostic labs.

    “Zebrafish, who share approximately 70% of their genes with humans, are a powerful model organism for genetic disorders,” shared Flanagan-Steet. “Since zebrafish embryos are clear, we can observe their development from the very beginning and learn how genetic factors lead to the disease-associated features that we see in patients.”

    “GGC is fortunate to have the expertise of both Dr. Steet and Dr. Flanagan-Steet, and we are excited as our research program expands to include our first animal model,” said Steve Skinner, MD, Director of GGC. “The potential of this new area of study is tremendous, and what we learn through their lab will undoubtedly move us closer to developing effective treatments for patients with rare genetic disorders.”

    Steet assumes the directorship from Charles Schwartz, PhD who joined GGC in 1985 as the Director of the Center’s Molecular Laboratory, and shifted his focus to lead research initiatives in 1996. Schwartz earned an international reputation in the area of X-linked intellectual disability. He remains on GGC faculty as a Senior Research Scientist. 

  • Sam Patrick posted an article
    State-of-the-art facility equipped with world-class labs, technologically advanced instrumentation see more

    The Clemson Center for Human Genetics officially opened for business Tuesday evening, celebrating with an enthusiastic gathering of supporters who met with scientists and toured the state-of-the-art facility.

    Piloted by a cadre of researchers equipped with world-class laboratories and technologically advanced instrumentation, Clemson’s Center for Human Genetics has successfully landed on the global stage – both in talent and scope. The center, which is part of Clemson’s College of Science, is dedicated to advancing knowledge of the fundamental principles by which genetic and environmental factors determine and predict healthy traits and susceptibility to disease.

    The center is housed in Self Regional Hall with eight laboratories and several classrooms, conference rooms and offices for faculty and graduate students. The 17,000-square-foot building is located on the campus of the Greenwood Genetic Center. During Tuesday’s event, the labs and hallways were jammed with guests.

    Trudy Mackay, director of the Center for Human Genetics, is recognized as one of the world’s leading authorities on the genetics of complex traits. Mackay, the Self Family Endowed Chair in Human Genetics and Professor of Genetics and Biochemistry, is a fellow of the American Association for the Advancement of Science. She has also been elected to the American Academy of Arts and Sciences, the Royal Society of London and the National Academy of Sciences.

    Mackay is joined at Clemson by Robert Anholt, Provost’s Distinguished Professor of Genetics and Biochemistry and director of Faculty Excellence Initiatives in the College of Science. Anholt is also a member of the American Association for the Advancement of Science.

    “This is an exciting time in the field of human genetics and its connection to health and well-being,” said Mackay, who has won numerous international awards, including the prestigious Wolf Prize, published more than 200 papers and trained graduate and postdoctoral students who have gone on to represent the next generation of geneticists. “We now know that all of us are 99.9 percent identical in our DNA, but that 10th of a percent difference translates to 3 million small genetic differences between any two of us. The challenge now is to understand how these molecular differences in DNA affect our susceptibility to diseases like cancer and heart ailments.”

    Tuesday’s event was the culmination of 13 years of planning, collaboration and diligence. The naming of Self Regional Hall recognized the ongoing support from Self Regional Healthcare, which has contributed $5.6 million to the facility. In addition, the $4 million endowed chair held by Mackay was funded equally by the Self Family Foundation and the state of South Carolina.

    “We are confident that our investment in the Self Family Endowed Chair for Human Genetics will pay huge dividends in furthering research to prevent, treat and cure genetic disorders,” said Frank Wideman, president of the Self Family Foundation. “We believe the synergy brought about by the intellectual capital of the Clemson Center for Human Genetics and that of the Greenwood Genetic Center has unlimited potential.”

    Clemson University President James P. Clements praised the Self family, the city of Greenwood, Greenwood County, the Greenwood Commissioners of Public Works and the Greenwood Partnership Alliance for their generous support.

    “Our partnership with the Greenwood Genetic Center, along with the amazing support we are receiving from Self Regional Healthcare and the Self Family Foundation, will allow our faculty researchers to translate their findings into tangible treatment options more quickly and efficiently,” Clements said. “The work being done here has the potential to make a huge difference in improving lives, which is at the core of Clemson’s mission as a land-grant university.”

    Mackay and Anholt came to Clemson from North Carolina State, where they had conducted research for a combined 55 years. Most of Mackay’s new Clemson team also hail from N.C. State, including staff scientists Richard Lyman and Roberta Lyman, postdoctoral research associate Chad Highfill and doctoral students Brandon Baker and Sneha Mokashi. Rebecca Jones, who graduated with a bachelor’s degree in genetics from Clemson in May 2018, will be joining the team as a graduate student. Karl Kelly will continue to provide support as director of operations.

    The Center for Human Genetics will work in partnership with the Greenwood Genetic Center, a nonprofit institute that focuses on clinical genetic services, diagnostic laboratory testing, educational programs and research. Mackay and her team will interact regularly with Greenwood Genetic Center personnel.

    “This is an outstanding example of how the power of partnership can collectively harness talent to improve lives,” said Cynthia Y. Young, founding dean of Clemson’s College of Science. “Together, we have put a stake in the ground to develop a globally recognized center of excellence around human genetics anchored by some of the world’s most talented scientists.”

    Dr. Steve Skinner, director of the Greenwood Genetic Center, said that the impact of the collaboration between the two centers will be transformative for genomics medicine.

    “With the research expertise of Drs. Mackay and Anholt, and GGC’s illustrious history of providing clinical care and human genetics advancements, our combined efforts will advance the understanding of human diseases and behaviors, as well as guide us toward potential treatments to improve the quality of life for those impacted by neurodevelopmental and other genetic disorders.”

    Skinner cited the recent joint acquisition of a NovaSeq 6000 DNA sequencer from Illumina as proof of the potency of the partnership.

    “The NovaSeq is the most powerful sequencer available, and we have the only one in South Carolina,” Skinner said. “This instrument not only increases our DNA sequencing capacity and ability to diagnose complex patients though whole genome sequencing, it also provides genomic data to advance Clemson’s studies and GGC’s zebrafish models with the ultimate goal of improving patient health and quality of life.”

    The main goals of the Center for Human Genetics include:

    • Leverage comprehensive genetic approaches and comparative genomics to explain the fundamental principles of human complex traits, including disease risk.

    • Promote precision medicine.

    • Develop local, regional, national and international collaborations to advance human genetics.

    • Educate the next generation of human geneticists.

    • Promote public understanding of human genetics through community outreach.

    Much of the above will be accomplished by studying the inner workings of an insect that is smaller than a grain of rice. The fruit fly Drosophila melanogaster has turned out to be a remarkably powerful gene discovery system for large-scale, population-based genetic studies. About 70 percent of fly genes have human counterparts, which enable the construction of contextual genetic networks. Using the fly as their catalyst, Mackay and her team will seek new breakthroughs in the treatment of addiction, glaucoma, alcohol and fatty liver disease, oxidative stress, heavy metal toxicity, aging and neurological disorders.

    “I am proud to lead Clemson’s Center for Human Genetics in Greenwood,” Mackay said. “We will have a strong connection to the main campus at Clemson to strengthen our research and academic core. Together with our partners, we will accomplish a great deal in the coming years.”

  • Sam Patrick posted an article
    TSO3 to Commercialize the STERIZON VP4 Sterilizer and Support Getinge Transition see more

    Myrtle Beach, United States and Quebec City, Canada August 1st, 2018 – TSO3 Inc. (TSX: TOS) (“TSO3” or the “Company”), an innovator in sterilization technology for medical devices, today announced that TSO3 and a fund (the “Fund”) of which Courage Capital Management LLC, (“Courage”) is the investment advisor, have entered into a binding US$20 million debt financing to fund commercialization initiatives for its STERIZONE® VP4 Sterilizer, the only terminal sterilization method that is FDA cleared to sterilize multi-channeled flexible endoscopes (with a maximum of four channels) of up to 3.5 meters in length, such as certain colonoscopes, gastroscopes and duodenoscopes. Courage is a Nashville, TN headquartered alternative asset management firm with a 20-year track record of investments in health care services, medical devices, and pharmaceuticals.

    Concurrent with the Courage financing, TSO3 and Getinge Infection Control AB (“Getinge”) mutually decided not to renew the distribution agreements between the parties, and have agreed to: 1) provide TSO3 unrestricted independent commercialization of its STERIZONE® VP4 Sterilizers; 2) the Company’s purchase of approximately 230 STERIZONE® VP4 Sterilizers, 220 of which are from Getinge’s inventory, for $33,000 per sterilizer; 3) transfer Getinge’s existing sales pipeline to TSO3 in exchange for shared economics at the completion of sale; and 4) transition to TSO3 the service, maintenance and consumables sales of all existing STERIZONE® VP4 Sterilizer customers in the United States and Canada. Getinge and TSO3 envision maintaining an ongoing collaborative relationship where TSO3 supplies and supports the STERIZONE® VP4 Sterilizer to satisfy Getinge customers looking for a total sterilization solution.

    About the STERIZONE® VP4 Sterilizer

    The STERIZONE® VP4 Sterilizer is a low-temperature sterilization system that utilizes the dual sterilants of vaporized hydrogen peroxide (H2O2) and ozone (O3) to achieve terminal sterilization of heat and moisturesensitive medical devices. Its single pre-programmed cycle can sterilize a large number and wide range of compatible devices, creating a cost-effective sterilization process with error-free cycle selection. The device’s unique Dynamic Sterilant Delivery System™ automatically adjusts the quantity of injected sterilant based on the 3 load composition, weight and temperature. This capability removes the guesswork and potential for human error, as there is no need to sort instruments and choose the appropriate cycles as with other machines.

    The STERIZONE® VP4 Sterilizer is the only terminal sterilization method that is FDA cleared to sterilize multichanneled flexible endoscopes (with a maximum of four channels) of up to 3.5 meters in length, such as video colonoscopes, duodenoscopes and gastroscopes – an industry first for any medical device sterilization process.

    The STERIZONE® VP4 Sterilizer is also the only cleared low temperature sterilizer that can process a mixed load consisting of general instruments, single channel flexible endoscopes, and single or double channel rigid endoscopes in the same cycle with load weights of up to 75 lb. The ability to run mixed loads significantly reduces labor costs by minimizing the amount of instrument sorting required, while maximizing the device turns (more productivity from increased throughput capacity).

    More information about the STERIZONE® VP4 Sterilizer is available through TSO3‘s website, under the Products section.

    About TSO3

    Founded in 1998, TSO3‘s activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSO3 also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.

    To read more about any of the following, please click here:

  • Sam Patrick posted an article
    NEW LIFE SCIENCES DISTRICT KICKS OFF CONSTRUCTION IN CHARLESTON, SC AT WESTEDGE see more

    Charleston, SC - July 17, 2018 marked the construction kickoff for 22 WestEdge, a striking new workplace anchor for the city’s growing knowledge economy and the highly anticipated centerpiece of the WestEdge District. The iconic 125-foot, eight-story structure will be the tallest multi-tenant office building on the peninsula and in Charleston’s metropolitan area when it opens in November 2019.

    “22 WestEdge affirms the vision for a Live, Learn and Earn district, adding vital office, research and lab components to the world class WestEdge community. It builds on the remarkable momentum of a development that already has over $300 million under construction,” said Michael Maher, CEO of The WestEdge Foundation, Inc., the non-profit sponsor of the overall development.

    Even prior to the 22 WestEdge groundbreaking, area economic development proponents including The Medical University of South Carolina, the South Carolina Research Authority, the City of Charleston, Heritage Trust and the WestEdge Foundation committed to 22 WestEdge, forming the nucleus of entities working to incubate, attract and retain entrepreneurial talent to energize the Charleston economy.  While 48% of the space is currently leased, 72,000 square feet of office space and 10,000 square feet of retail space remain available for existing local businesses, or for new companies being created or relocating to the Charleston region. This is a remarkable concentration of ingenuity¾over 35,000 people live, work, study and seek healthcare expertise in the adjacent medical district.

    Partnership and innovation opportunities abound for 22 WestEdge tenants—with unprecedented access to like-minded neighbors and colleagues in Charleston’s life sciences sector. Dr. David Cole, President of MUSC shared, “With MUSC’s $275 million of research and proprietary discoveries, 22 WestEdge will allow the University to collaborate with private industry to create new healthcare solutions, new companies and recruit existing global medical-related companies to Charleston.” Bob Quinn, Executive Director of the SCRA agreed, “SCRA’s leasing of the entire top floor of 22 WestEdge will allow us to create a world-class facility, including laboratories, which will serve as a catalyst for the attraction of leading life sciences companies and the creation of a Discovery District adjacent to MUSC.”  

    Charleston Mayor John Tecklenburg echoed, “It’s no secret that biomedical advances will be a key driver of our economy and society in the years ahead. With 156,000 square feet of office space dedicated to precisely the kind of research and enterprise that will help make those breakthroughs possible, 22 WestEdge is a welcome and important addition to our city’s medical district.”

    22 WestEdge office tenants will also benefit from the energy and vitality of the district. Recently completed, The Caroline has 237 apartments and 20,000 square feet of retail and restaurant space, and the topped-out 10 WestEdge will have 350 residential units, a Publix Super Market, Woodhouse Spa and additional retail and restaurant space, providing an abundance of shopping, eating and living options for all. 22 WestEdge’s own amenities include 15,000 square feet of cafes and fitness facilities, common conference and event facilities and a terrace wrapping the 7th floor with sweeping views of the Ashley River. Mack Reese, 22 WestEdge developer and partner, explains his reason for developing the project, “With its access to parking, numerous retail amenities and an urban density of residential opportunities for employees, the building will be a new and exciting option for existing Charleston businesses and those looking to relocate to the region.”

    Upon completion, WestEdge’s master-planned mixed-use district will encompass more than 3,000,000 square feet of space on 60 acres along the Ashley River adjacent to MUSC and the Medical District, and fronting on Brittlebank Park and the Joseph Riley Baseball Stadium. WestEdge is a public-private partnership created to advance economic development and expand the research capabilities of the Medical University of South Carolina and foster new companies and collaborative opportunities with private industry. It is an innovative redevelopment that is transforming the quality of life for Charleston’s west side.

    Key 22 WestEdge partners include Gateway Development (Developer) ELV Associates (Investor), BB&T (Lender), Trident Construction (General Contractor), Perkins & Will (Architect), Thomas and Hutton (Civil Engineer), and Lee & Associates (Marketing & Leasing).  

    For leasing inquiries and further detail on WestEdge development, please contact Mack Reese of Gateway Development (770-310-3414 ).  

  • Sam Patrick posted an article
    MUSC receives grant for expansion of telehealth program see more

    The Medical University of South Carolina (MUSC) palliative care program has received a $1,278,000 grant from The Duke Endowment to create a statewide, palliative care telehealth program.

    Providing end of life and comfort care to those in need, especially for the state’s most vulnerable and rural populations, is the primary aim of the new effort. Program leadership expects not only an improvement to accessibility for this kind of care, but also potential cost savings to individual patients and the system as a whole.  Click for full details.

  • Sam Patrick posted an article
    Moterum selected to present at prestigious medtech conference in Chicago, IL see more

    Southeastern medtech company develops mobility solutions for patients suffering from strokes, neural traumas; forum convenes investors seeking leading-edge advances in health and life sciences

     

     

    GREENVILLE, S.C. July 11, 2018Moterum Technologies Inc., a South Carolina-based mobility and gait rehabilitation development company, has been selected to present at the prestigious Cavendish BioHealth Impact Forum July 17-18, 2018 in Chicago, Illinois.  The Forum provides an environment for organizations and investors to further their strategic social impact investing, grant-giving, and philanthropy programs in support of health and life sciences advances. 

    Co-hosted by Cavendish Global, the Shirley Ryan AbilityLab, and MATTER, the Forum showcases presentations and panel discussions by leading research institutions, private-sector companies, nonprofit organizations, and foundations engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment.  Cavendish BioHealth Impact Forums are hosted by leading institutions around the United States and take place several times each year.

    Moterum Technologies is one of 10 featured organizations invited to present their solutions at the Chicago Conference.  An innovative medical technology development company, Moterum’s focus is designed to help resolve mobility and gait problems for patients suffering a neural trauma, such as a stroke.  Its lead product is a fully connected, smart device that teaches stroke patients how to re-learn walking in their own home.

    “We are honored to be selected to present at the 2018 Chicago Forum, and value the recognition it will provide of our innovative approach to helping stroke survivors walk independently and without a limp or asymmetry,” said David Huizenga, CEO of Moterum Technologies.  “Our device can be used at home and is fully connected and positioned for telehealth systems, making it a viable solution for developed and developing health systems alike.  We welcome the chance to interact with many of the world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to improving the health and lives of people around the world.”

    The Cavendish community consists of over 200 leading family offices, foundations and impact investors from around the world with combined assets of over $225 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish BioHealth Impact Forum provides impact investors with a curated, peer-to-peer knowledge expansion and relationship building environment, and seeks to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing.  The Forum is also an opportunity for impact investors to champion and share information on projects and organizations, which they are passionate about with other impact investors from around the world.

    “With the help of our expert team, Selection Committee and advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence,” said J. Michael Moffat, Chairman of Cavendish Global.  “The quality and originality of Moterum Technologies’ research and scientific insights in treating gait problems of stroke survivors positions them to make a major contribution to global health by helping stroke survivors retake an independent position in society.”

    For further information on Moterum Technologies, visit www.moterum.com.  


    About Moterum Technologies Inc.

    Moterum Technologies is an innovative medical technology development company that focuses on solving mobility and gait problems for patients suffering a neural trauma, such as a stroke.  Its lead product is a fully connected, smart device that teaches stroke patients to relearn how to walk in their own home.

  • Sam Patrick posted an article
    Study to investigate potential impact to outcomes for several difficult-to-treat solid tumors see more

    3D-PREDICT Study to investigate potential impact to outcomes for several difficult-to-treat solid tumors

     

    GREENVILLE, SC. – June 20, 2018 – KIYATEC, Inc. today announced the enrollment of the first patients in a U.S. clinical study of its Ex Vivo 3D drug response assay (EV3D™) across several difficult-to-treat solid tumors. The 3D-PREDICT clinical study has been initiated at the Cancer Institute of Greenville Health System (GHS) with the goal of recruiting 640 patients across additional clinical sites to be added in the future.

    The 3D-PREDICT Study is a prospective, open-label, multi-institutional, non-interventional study to validate the EV3D assay for clinical use and to investigate the impact on outcomes for cancer patients with both newly diagnosed and recurrent epithelial ovarian cancer and recurrent high-grade gliomas, which include glioblastomas (GBM). Over the next year or so, the study will expand to include patients with newly diagnosed high-grade gliomas, high-grade rare tumors and triple negative breast cancer. The primary objectives of the study are to establish correlation between assay predicted drug response and patient clinical outcomes, and to measure the potential impact of the assay on therapeutic decision-making. The study is anticipated to continue through 2022. Details on the trial can be found on ClinicalTrials.gov

    The EV3D assay platform assesses a patient’s own cancer cells within a biologically relevant 3D culture microenvironment to provide individualized response prediction to specific therapeutic agents. In this study, the therapeutic agents predicted consist of available, guideline recommended drug options for each cancer type. 

    “As an institution, we’ve supported KIYATEC’s pilot clinical studies by providing over 450 samples of cancer tissues spanning the multiple tumor types they are testing and our clinical investigators are ready to take this important next step,” said Larry Gluck, MD, Medical Director of the GHS Cancer Institute. “Patients with recurrent ovarian cancer and recurrent GBM are among those with the most challenging prognosis at every cancer center around the country. The fact that KIYATEC is offering us a new tool in these very difficult to treat populations is a needle mover for these patients coming to Greenville for their treatment.”

    “Patients with these kinds of newly diagnosed and recurrent cancers simply do not have the luxury of time on their side. Their time, health and money spent on a treatment that is not working can have devastating consequences that we all want to avoid,” said Matthew Gevaert, CEO of KIYATEC. “The commencement of this clinical trial builds upon the success of our pilot studies and represents a significant milestone toward our goal of helping cancer patients receive the best treatment at the earliest possible time.”


    About KIYATEC, Inc.

    KIYATEC is changing the future of cancer care by accurately predicting patient-specific response and non-response to chemotherapy drugs before treatment begins. Wasted time is the enemy of cancer patients and there is currently no way to accurately predict which cancer patients will respond to standard oncology treatments. KIYATEC has developed a validated process to use a cancer patient’s own live cells to accurately predict treatment response prior to beginning treatment.

     

    About Greenville Health System

    Greenville-based Greenville Health System (GHS) has partnered with Columbia-based Palmetto Health to form a not-for-profit health care delivery system serving 1.2 million patients annually across South Carolina. The new name and graphic identity are expected to be announced later this year. GHS offers patients an innovative network of clinical integration, expertise and technologies through its academic health system, eight medical campuses, tertiary medical center, research and education facilities, community hospitals, physician practices and numerous specialty services. GHS, by itself a 1,627-bed system, is home to 16 medical residency and fellowship programs, as well as partnership efforts such as the University of South Carolina School of Medicine Greenville and the soon-opening Clemson University Center for Nursing, Health Innovation and Research. Visit www.ghs.org for more information.

  • Sam Patrick posted an article
    South Carolina's life sciences industry is booming. Read on for details... see more

    From pharmaceuticals and medical devices to research and laboratory testing, the state's life sciences field is booming.  The Charleston and Lowcountry region is home to many established companies and start-ups making a mark on the biomedical and health industries.  Read on for the full story from Charleston Business Magazine's 2018 State of the Lowcountry Report.

  • Sam Patrick posted an article
    IVC, which produces dietary supplements, prescription and OTC products, is expanding. see more

    Company produces high quality dietary supplements, plus nutritional, prescription and OTC products, for leading U.S. and global retailers and contract customers

     

    GREENVILLE, S.C. June 18, 2018 – International Vitamin Corporation (IVC), which produces high quality dietary supplements along with nutritional, prescription and OTC products, will invest several million dollars and add a significant number of positions to expand operations at its Greenville County, S.C. facilities over the next several years.

    Founded more than 55 years ago, IVC produces high quality dietary supplements for leading food, drug, mass and club retailers in the United States. The company also produces nutritional, prescription and OTC products for contract customers around the world. IVC’s recognized ability to deliver on innovation, quality and supply chain efficiency has enabled IVC to become one of the largest and fastest growing private label nutritional supplement companies in the nutritional marketplace.

    “This expansion of our Greenville County presence represents an important step in the growth of our business,” said Steven Dai, President and CEO for International Vitamin Corporation. 

    “We have found Greenville County and the Upstate a welcoming and pro-business location to expand our business, serve our customers and accelerate IVC’s success as we focus our efforts on meeting growing demand from our customers,” Dai added.  “We appreciate the support of the Greenville Area Development Corporation, the city of Greenville, the South Carolina Department of Commerce, and all who joined to make this announcement a reality.”

    IVC will expand its operations at 4615 Dairy Road and 4611 Dairy Road in Greenville County, already employing more than 380 associates.  IVC will create “a meaningful number of additional skilled and professional positions in Greenville County over the next several years,” said Jill Stambler, Vice President Human Resources.

    “Greenville County is pleased with International Vitamin Corporation's decision to expand its business operations in Greenville County by producing well known dietary supplements and pharmaceutical products to the US and international markets as it has for over 50 years,” said H.G. “Butch” Kirven, Chairman of Greenville County Council. “This expansion means significant additional capital investment by the company here, coupled with a commitment to increasing job opportunities for local citizens.  The company's decision reflects the high caliber of Greenville county's workforce, our low tax rates, and the unparalleled quality of life unique to our area.”

    “IVC’s focus on the vitamins, minerals and supplements market and innovations in both manufacturing and supply chain show that our community continues to be a profitable place to do business,” said City of Greenville Mayor Knox White. “The expansion of their manufacturing facility along the I-85 corridor is further affirmation that Greenville is open for business and we are thankful for the IVC family’s trust and continued investment.”

    Hiring details for the additional positions to be filled will be announced in the near future, according to Stambler.  She adds, “We are currently looking for a number of positions on different shifts.”  Some include: 

    • Set-up Mechanics
    • Material Handlers
    • Operators
    • Turret Drivers
    • Manufacturing Supervisors
    • Warehouse Clerk
    • Warehouse Order Pickers
    • Warehouse Shippers

    Interested candidates may apply directly at the IVC website by visiting http://ivccareers.com.

    For more information about International Vitamins Corporation, visit them at www.ivcinc.com.

     

  • Sam Patrick posted an article
    SCRA Collaboration Center Awards feature numerous life science organizations from across the state. see more

    South Carolina Research Authority’s SCRA-Academia Collaboration Team announces nearly $600,000 in feasibility grants for six projects. The awarded projects encourage collaboration between academic institutions and industry partners to advance commercially relevant research and establish the feasibility of the formation of Collaboration Centers. These Collaboration Centers will be founded for those areas demonstrating a critical mass of talent, infrastructure, financial resources, intellectual property and the prevalence of industry in South Carolina.

    “These Feasibility Grants are the first step in establishing Collaboration Centers, which will garner national recognition for South Carolina, create jobs, engage industry and have an overall positive impact on the state.” said Christine Dixon Thiesing, Director of Academic Programs. “SCRA is fostering the growth of collaboration across academic institutions and between academia and industry through the support of six innovation projects.”

    The Feasibility Grant Awards are the result of the efforts of the SACT, which was formed to deliver outcomes aligned with the Strategic Collaboration Agreement signed by SCRA and the presidents of the state’s research universities. The SACT is composed of representatives from the research universities, comprehensive teaching institutions, technical colleges, industry and SCRA. The SACT is currently evaluating the feasibility of establishing three Collaboration Centers – a Composites Industry Solutions Center, Medical Devices Collaboration Center, and Technology-Enabled Population Health Collaboration Center.

    The list of grant awardees is below:

    Composites Industry Solutions Center:
    Collaboration among Clemson University, Greenville Technical College and industry partners Kistler Instrument Corp., Keyence Corporation of America and Renishaw.

    Medical Devices Collaboration Center:
    Collaboration between the Medical University of South Carolina and Clemson University.

    Technology-Enabled Population Health Collaboration Center:
    Collaboration among the Medical University of South Carolina, Trident Technical College and industry partners Zeriscope, Inc. and Amanda Senior Care.

    Collaboration between Francis Marion University and a regional health organization as the industry partner.

    Collaboration among University of South Carolina – Upstate and industry partners ChartSpan Medical Technologies and a state agency.

    Collaboration among Clemson University, Florence-Darlington Technical College’s Southeastern Institute of Manufacturing and Technology and industry partner Greenville Health System.

  • Sam Patrick posted an article
    ZEUS Industrial has acquired MWC Technologies, LLC see more

    ORANGEBURG, S.C., June 11, 2018 -- Zeus Industrial Products, Inc. (Zeus), a leading polymer extrusion manufacturer and material science innovator, today announced that it has acquired MWC Technologies, LLC (MWC). This adds to the capabilities that Zeus has been developing for the past five decades.

    MWC, a manufacturer of medical device components based in Chattanooga, TN, possesses innovative technologies that support Zeus' growth strategy. This acquisition will allow for the global commercialization of the many cutting-edge, solution-driven products in MWC's portfolio.

    Click to Tweet: @ZeusTubing acquires MWC Technologies: https://www.zeusinc.com/2018/06/11/zeus-acquires-mwc-technologies-llc/


    COMMENTS

    "Since I founded the company in 1966, Zeus has been focused on continuing to grow and innovate. This acquisition supports those goals. We are confident that our acquisition of MWC  will provide value to our customers today and into the future.." – Frank P. Tourville, Sr., Founder and Chairman of the Board, Zeus Industrial Products, Inc.

    "The acquisition of MWC  will expand our capabilities and product portfolio to address the rising demand for advanced precision extrusions. Our combined expertise will enhance our ability to better serve customers around the globe." – John Winarchick, CEO, Zeus Industrial Products, Inc.

    "We are excited to be joining the Zeus team!  Zeus's long term commitment to industry leading quality, customer service and innovation aligns well with MWC's culture.  Our combined technologies will enable new to the market solutions for our customers." – Eric Avans, Quality Manager, MWC Technologies

    RESOURCES

    Zeus Industrial Products: Learn more about the company and its products on the Zeus website; or call toll-free 1-800-526-3842 or +1-803-268-9500 outside the U.S.

    ABOUT ZEUS INDUSTRIAL PRODUCTS, INC.

    Zeus Industrial Products, Inc., is headquartered in Orangeburg, SC, USA. Its core business is the development and precision extrusion of advanced polymeric materials. The company employs over 1,500 people worldwide with manufacturing facilities in Aiken, Gaston and Orangeburg, South Carolina; Branchburg, New Jersey; and Letterkenny, Ireland. Zeus products and services serve companies in the medical, automotive, aerospace, fiber optics, energy and fluid management markets. For more information, visit www.zeusinc.com.

  • Sam Patrick posted an article
    U.S. bioscience industry has reached $2 trillion in annual economic impact while continuing to grow see more

    Boston, MA (June 5, 2018) –  A study released today at the BIO International Convention shows that the U.S. bioscience industry has reached $2 trillion in annual economic impact while maintaining accelerated venture capital investment and job growth numbers. Among U.S. technology sectors, the bioscience industry has held a leading position as an economic driver and job generator.

    The report, Investment, Innovation and Job Creation in a Growing U.S. Bioscience Industry 2018, finds U.S. bioscience firms directly employ 1.74 million people, a figure that includes more than 273,000 high-paying jobs created since 2001. The average annual wage for a U.S. bioscience worker reached $98,961 in 2016. These earnings are more than $45,000 greater, on average, than the overall U.S. private sector wage. The report further shows that since 2014, the bioscience industry has grown by 4.4 percent with four of its five major subsectors contributing to this overall job gain.

    For the first time, the biennial report includes a full assessment of the economic impact of the bioscience industry and finds its total economic impact on the U.S. economy, as measured by overall output, totaled $2 trillion in 2016. This impact is generated by the direct output of the bioscience industry combined with the indirect (supply chain) and induced (employee spending) impacts. The industry and its associated economic output support 8 million jobs throughout the entire U.S. economy through both indirect and induced effects.

    “This report highlights the enormous economic impact delivered by our industry. This strong performance is due to the vital and wide-ranging collaborations between industry partners, universities, and policymakers that provides a business climate that supports the development of innovative bioscience products and high paying jobs,” said Jim Greenwood, President and CEO of the Biotechnology Innovation Organization."

    The report also takes the pulse of the broader U.S. innovation ecosystem for bioscience companies and finds it advancing with positive results. The U.S. is experiencing strong gains in bioscience venture capital funding, growth in patents, a recent ramp-up in bioscience-related university R&D expenditures and increasing research funding from the National Institutes of Health (NIH).

    “The bioscience industry is vital to the U.S. not only as an innovation engine that is improving lives, but also as a major economic driver that is consistently generating high-quality jobs and significant economic output across the nation,” said Ryan Helwig, Principal and Project Director with TEConomy Partners.

    The state-by-state industry assessment is the eighth in a biennial series, developed in partnership by TEConomy and BIO, presenting data on national, state, and metropolitan area bioscience industry employment and recent trends.

    Additional highlights from the industry economic analysis include:

    • The industry is a major economic driver and is well distributed across U.S. states and cities:
      • 41 states experienced net job growth in the biosciences between 2014-2016
      • 38 states and Puerto Rico have an employment specialization in at least one bioscience subsector
      • 213 of 383 U.S. metropolitan areas have at least one bioscience specialization

    Highlights from the analysis of the innovation ecosystem for the bioscience industry include:

    • Strength in recent venture capital and patenting trends:
      • Venture capital investments have reached new highs. More than $66 billion in venture capital was invested in bioscience companies during the 2014 through 2017 period, including a new annual high in 2017 at $20 billion invested.
      • Innovation continues to drive the biosciences, since 2014 the U.S. has increased patent totals in bioscience-related technology classes by nearly 5 percent, or 1.6 percent per year, on average. 2017 had a total of nearly 27,000 patents awarded to U.S. inventors, another new high.
    • Growth for academic biosciences R&D in 2016
      • After several years of concerns raised about the declining and/or flat NIH research budgets and the subsequent effects on academic and other research, NIH funding is back on the rise. There have been budget increases sustained each of the last three years.
      • Across America’s colleges and universities, the pace of R&D spending in bioscience-related research areas has increased. Following a 1.5 percent decline in 2015, academic R&D expenditures in the biosciences increased 5.5 percent to $42 billion in 2016.

  • Sam Patrick posted an article
    South Carolina Named Top 3 in Best States for Business see more

    South Carolina has another opportunity to promote its economic development prowess thanks to a magazine’s business climate rankings.

    The Palmetto State tied for third with North Carolina in Chief Executive’s 2018 “Best and Worst States for Business.” Texas was No. 1, followed by Florida. Indiana was fifth.

    “A high ranking like this is a great tool that drives industrial prospects to consider South Carolina and our region for new investment and jobs,” says Will Williams, president and chief executive of the Economic Development Partnership, which serves Aiken, Edgefield, McCormick and Saluda counties.

    It was a slight improvement for the Palmetto State, which finished fourth in 2017. Economic development officials say there’s value in “best” lists.

    “We certainly use these types of rankings in our marketing to differentiate ourselves from other states and regions,” says John Lummus, president and chief executive of the Upstate SC Alliance, which serves a 10-county region. “I feel that these rankings are important not only because they shine a light on the positive, but also often show where improvements may need to be considered.”

    This latest ranking, which is based on a survey of CEOs, is in its 14th year. Publications devoted to business and/or economic development produce various types of state-by-state rankings throughout the year.

    “The Palmetto State consistently scores near the top due to a number of factors, such as low unionization rates, strong cooperation between government and business, low-cost utilities, established transportation and infrastructure, competitive wage rates, and availability of a talented workforce,” Lummus says.

    South Carolina ranked 10th overall in the Chief Executive rankings in 2015, fifth in 2014 and eighth in 2013.

    “This doesn’t just happen by accident,” says David Ginn, president and chief executive of the Charleston Regional Development Alliance. “The S.C. Department of Commerce is one of the best-performing economic development teams in the country.”

    Texas, Florida and North Carolina have been one-two-three for each of the past four years. Texas has been No. 1 all 14 years of the ranking’s existence.

    “The difference between the top five states is negligible, roughly within the statistical margin of error,” says John O’Toole, executive director of the Beaufort County Economic Development Corp.

    Meanwhile, California anchored the bottom of the list at No. 50 for the seventh consecutive year. The seven lowest-ranked states were all the same as in 2017.

    The magazine speculated that the reputations, leadership and governing philosophies in the top and bottom states don’t change much, while states in the middle of the rankings move up and down in response to those factors.

    “Our legislature has provided us tools to be competitive and our state and local permitting agencies understand the importance of keeping it simple,” Williams says. “Our collective economic development team has an enviable global reputation for delivering projects, both big and small, on time. And our focus on existing industry success demonstrates we take good care of you once you get here.”

    This year, the magazine noted that South Carolina was a right-to-work state and cited the South Carolina Innovation Plan, an initiative to support the advanced manufacturing, life sciences, biotech and computer software sectors.

    “In our targeted industries – aerospace, agribusiness, automotive, manufacturing and technology industries – we can compete with any state or nation,” O’Toole says.

    There were three subcategories used in the ranking: taxation/regulation, workforce quality and living environment. South Carolina ranked 10th, 14th and seventh in those three categories, respectively.

    Living environment is a selling point for O’Toole.

    “To punctuate our value proposition, at the end of the day you can be in Hilton Head, Beaufort, Bluffton or Port Royal,” he says. “What could be finer?”

    The Charleston area also makes many “best” lists related to quality of life and tourism.

    “National rankings make great headlines so we use them to grab attention and reinforce our strengths as a globally attractive location for business and talent,” Ginn says.

  • Sam Patrick posted an article
    KIYATEC growth supports upcoming programs to better predict patient response to oncology drugs see more

    GREENVILLE, SC. – May 29, 2018 – KIYATEC, Inc., a privately held company changing the future of cancer care by predicting patient response to oncology drugs prior to treatment, today announced an expansion of its leadership team with the appointment of two industry veterans. Charlene Knape has joined the company as Vice President of Clinical Affairs, and Timothy Decker as Vice President Commercial Operations.

    Mr. Decker, a twenty year industry leader with a proven track record of developing and commercializing oncology diagnostic services and pharmaceuticals, has assumed responsibility for pre-launch commercial strategic development along with tactical planning and execution to drive clinical product launches. Mr. Decker held roles of increasing responsibility in strategic and tactical marketing for a decade at G.D. Searle and Abbott Laboratories before joining Genomic Health, Inc.  Over an eight year span, he played a lead role as Director and Senior Director in the global launch, marketing, reimbursement and sales of Oncotype DX molecular diagnostic tests in breast, colon and prostate cancers. Mr. Decker subsequently served as Vice President of Marketing at Castle Biosciences, Inc., where he drove corporate and pipeline strategy, as well as in-line product strategy and revenue growth for its molecular diagnostic tests in melanoma. He joins the company from Mexico City-based Grupo Fármacos Especializados, where he served as Division Head, Oncology Diagnostics, responsible for developing reimbursement pathways and securing positive coverage decisions among public and private sector payers.

    With more than 25 years of experience working with diagnostic companies, Ms. Knape is responsible for leading the clinical development programs and clinical operations for KIYATEC’s pipeline for ovarian cancer, glioblastoma, rare tumors and triple negative breast cancer. She most recently served as Senior Director, Clinical Development for Inivata, a clinical cancer genomics company utilizing liquid biopsies for comprehensive genomic profiling of tumors. Prior to this, Ms. Knape served in Becton Dickinson’s Corporate Clinical Development group, responsible for global clinical quality and contracts. Ms. Knape spent five years with Micell Technologies as Senior Director of Clinical Affairs where she managed all global clinical activities for first-in-human and CE Marking studies for an implantable cardiovascular device from initiation through successful regulatory submission. As the company’s lead in clinical operations, Ms. Knape also built the team and initiated a 1,400-patient study in Europe and a 400-patient study in China. Previously, Ms. Knape served as Vice President, Clinical Affairs at EndoTex Interventional Systems, led the clinical functions for Avocet Medical and Somnus Medical Technologies and held clinical affairs positions in the Companion Diagnostics and Biorepository at LabCorp.

    “At this pivotal time in the company’s growth, we are thrilled to welcome Charlene and Tim to KIYATEC. These two newly created positions are critical as we expand our clinical programs in key therapeutic areas and further strengthen our plan for the broad adoption of our patient-specific response prediction tests,” said Dr. Matthew Gevaert, CEO of KIYATEC. “Their expertise and industry knowledge is unparalleled and they will be instrumental as KIYATEC continues toward its path of changing the future of cancer care by predicting patient response to chemotherapy before treatment begins. I’m so glad to have Tim and Charlene on our team as we move toward our goal of commercialization and helping patients receive optimal treatment at the earliest possible time.”

    KIYATEC will be attending the American Society of Clinical Oncology (ASCO) meeting being held June 1-5 in Chicago.

    About KIYATEC, Inc.

    KIYATEC is changing the future of cancer care by accurately predicting patient-specific response and non-response to chemotherapy drugs before treatment begins. Wasted time is the enemy of cancer patients and there is currently no way to accurately predict which cancer patients will respond to standard oncology treatments. KIYATEC has developed a validated process to use a cancer patient’s own live cells to accurately predict treatment response prior to beginning treatment.